Business Context and Reporting Period
This Form 8-K was filed by Galectin Therapeutics Inc. on February 7, 2013, reporting events occurring on February 1, 2013. The filing details the entry into a material definitive agreement to support the company's clinical research operations.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. The only specific financial metric disclosed relates to the new contractual commitment:
- Estimated Work Order Budget: $2,155,440
- Upfront Startup Costs: Approximately $384,000
- Payment Structure: Remaining balance payable monthly or as costs are incurred.
Material Changes
The primary material change is the execution of an Amended and Restated Master Services Agreement with CTI Clinical Trial Services, Inc. and CTI Clinical Consulting Services, Inc. (collectively "CTI"). Key terms include:
- Agreement Term: Effective until January 31, 2018.
- Specific Work Order: Covers a Phase I Clinical Trial for the drug GR-MD-02 in subjects with Non-Alcoholic Steatohepatitis (NASH) with advanced hepatic fibrosis.
- Work Order Duration: February 1, 2013, to March 31, 2014.
- Services: CTI will handle IND safety reports, investigator selection, study monitoring, record keeping, and disposal of unused investigational drug.
Guidance, Risks, and Contingencies
The filing outlines specific termination rights and contingencies rather than forward-looking financial guidance:
- Termination for Convenience: Either party may terminate with 90 days' prior written notice.
- Immediate Termination: Permitted if the other party becomes insolvent, files for bankruptcy, or if the FDA withdraws study authorization.
- Safety Contingency: The Company may terminate immediately if medical or patient safety reasons dictate.
- Breach: Termination for material breach is allowed with 30 days' notice if the breach is not cured.
Investor Verification Checklist
- Verify the company's current cash position to ensure it can cover the $384,000 upfront startup costs and ongoing monthly payments.
- Confirm the status of the Investigational New Drug (IND) application for GR-MD-02 to assess the risk of FDA withdrawal.
- Review the company's pipeline to understand the strategic importance of the NASH Phase I trial relative to other assets.
- Monitor future filings for any amendments to the budget, as the $2,155,440 estimate is subject to change.